FRM
TCRT icon

Fox Run Management’s Alaunos Therapeutics TCRT Stock Holding History

Fox Run Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-162
Closed -$133K – 687
2016
Q2 		$133K Buy
+162
New +$176K 0.06% 486

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fox Run Management's TCRT Position: Q3 2016 in Review

Fox Run Management sold out of Alaunos Therapeutics (TCRT) in Q3 2016, closing a stake of 162 shares — an estimated $133K sold.

Fox Run Management first reported a position in TCRT in Q2 2016 and held it in 1 quarter. The position peaked at $133K in Q2 2016. 140 funds tracked by Wall St. Rank hold TCRT as of Q3 2016.

  • Fox Run Management reported no remaining Alaunos Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Fox Run Management sold 162 Alaunos Therapeutics shares in Q3 2016, an estimated $133K.
  • Fox Run Management first reported a position in Alaunos Therapeutics in Q2 2016 and held it in 1 quarter.
  • Fox Run Management's Alaunos Therapeutics position peaked at $133K in Q2 2016.
  • 140 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2016.

Based on Fox Run Management's 13F filing for Q3 2016, filed 12 Oct 2016.